42 filings
Page 2 of 3
8-K
nx6 9hhn9ic
3 Jun 21
Other Events
8:08am
8-K
cjz3ukihk4u 6i0y
6 May 21
Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights
4:03pm
8-K
z69q0oxc6sey
5 Apr 21
Oyster Point Pharma Announces New Appointment to Board of Directors
6:15am
8-K
3juq2
2 Mar 21
U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss this application
8:17am
8-K
mg3f6weo0r
18 Feb 21
Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
4:01pm
8-K
bu5jy9
18 Dec 20
Other Events
7:16am
8-K
go9i2cxc7nnkjzex78
2 Dec 20
Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021
9:37am
8-K
uwurut lltna1
5 Nov 20
Entry into a Material Definitive Agreement
5:24pm
8-K
hqfazsj62vpar3in80xw
5 Nov 20
Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights
4:01pm
8-K
tqne2wyyl1lvyiqc9u
9 Oct 20
Oyster Point Pharma Announces Board of Directors Leadership Changes and New
8:01am
8-K
rcepzx0xxi7lwwdgh73p
5 Aug 20
Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights
7:02am
8-K
75w75pdq3g1unl85
9 Jun 20
Regulation FD Disclosure
12:00am
8-K
tam1usvs6
5 Jun 20
Submission of Matters to a Vote of Security Holders
4:17pm
8-K
91g2wu tkqf95
15 May 20
Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock
8:00am
8-K
mbtncc9
11 May 20
Other Events
6:10am
8-K
r9xpetu
11 May 20
Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights
6:07am
8-K
cv9arcr ux67p
30 Mar 20
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020
7:33am
8-K
edrxcy ymt58
27 Feb 20
Oyster Point Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
4:09pm
8-K
0xvssm7
14 Jan 20
Regulation FD Disclosure
8:01am
8-K
ai0 sl1fvcduddz91
13 Jan 20
Regulation FD Disclosure
8:00am